153 related articles for article (PubMed ID: 11943414)
21. Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.
Pazzucconi F; Dorigotti F; Gianfranceschi G; Campagnoli G; Sirtori M; Franceschini G; Sirtori CR
Atherosclerosis; 1995 Oct; 117(2):189-98. PubMed ID: 8801864
[TBL] [Abstract][Full Text] [Related]
22. Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy.
Ballantyne CM; McKenney JM; MacDougall DE; Margulies JR; Robinson PL; Hanselman JC; Lalwani ND
Am J Cardiol; 2016 Jun; 117(12):1928-33. PubMed ID: 27138185
[TBL] [Abstract][Full Text] [Related]
23. Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
Sigurdsson G; Haraldsdottir SO; Melberg TH; Tikkanen MJ; Miettinen TE; Kristianson KJ
Acta Cardiol; 1998; 53(1):7-14. PubMed ID: 9638964
[TBL] [Abstract][Full Text] [Related]
24. Bezafibrate for primary biliary cirrhosis.
Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2012 Jan; 1():CD009145. PubMed ID: 22259000
[TBL] [Abstract][Full Text] [Related]
25. Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor.
Chapman BA; Burt MJ; Chisholm RJ; Allan RB; Yeo KH; Ross AG
Dig Dis Sci; 1998 Feb; 43(2):349-53. PubMed ID: 9512129
[TBL] [Abstract][Full Text] [Related]
26. Association of simvastatin and hyperlipidemia with periodontal status and bone metabolism markers.
Magán-Fernández A; Papay-Ramírez L; Tomás J; Marfil-Álvarez R; Rizzo M; Bravo M; Mesa F
J Periodontol; 2014 Oct; 85(10):1408-15. PubMed ID: 24555750
[TBL] [Abstract][Full Text] [Related]
27. Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans--in vitro and in vivo studies.
Vitols S; Angelin B; Juliusson G
Lipids; 1997 Mar; 32(3):255-62. PubMed ID: 9076662
[TBL] [Abstract][Full Text] [Related]
28. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid.
Vuoristo M; Färkkilä M; Karvonen AL; Leino R; Lehtola J; Mäkinen J; Mattila J; Friman C; Seppälä K; Tuominen J
Gastroenterology; 1995 May; 108(5):1470-8. PubMed ID: 7729640
[TBL] [Abstract][Full Text] [Related]
29. Lowering low density lipoprotein cholesterol with simvastatin, a hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, does not affect luteal function in premenopausal women.
Plotkin D; Miller S; Nakajima S; Peskin E; Burkman R; Richardson D; Mitchel Y; Waldstreicher J; Liu M; Shapiro D; Santoro N
J Clin Endocrinol Metab; 2002 Jul; 87(7):3155-61. PubMed ID: 12107216
[TBL] [Abstract][Full Text] [Related]
30. Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients.
Lansberg PJ; Mitchel YB; Shapiro D; Kastelein JJ; Altman R; Jerums G; Bolzano K; Giannini S; Davignon J; DeWailly P
Atherosclerosis; 1995 Aug; 116(2):153-62. PubMed ID: 7575771
[TBL] [Abstract][Full Text] [Related]
31. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era.
Jacobson TA
Am J Cardiol; 1996 Sep; 78(6A):32-41. PubMed ID: 8875973
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease.
Sano M; Bell KL; Galasko D; Galvin JE; Thomas RG; van Dyck CH; Aisen PS
Neurology; 2011 Aug; 77(6):556-63. PubMed ID: 21795660
[TBL] [Abstract][Full Text] [Related]
34. Effect of bezafibrate in primary biliary cirrhosis: a pilot study.
Ohmoto K; Mitsui Y; Yamamoto S
Liver; 2001 Jun; 21(3):223-4. PubMed ID: 11422787
[No Abstract] [Full Text] [Related]
35. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy.
Blair SN; Capuzzi DM; Gottlieb SO; Nguyen T; Morgan JM; Cater NB
Am J Cardiol; 2000 Jul; 86(1):46-52. PubMed ID: 10867091
[TBL] [Abstract][Full Text] [Related]
36. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels.
Ballantyne CM; Andrews TC; Hsia JA; Kramer JH; Shear C;
Am J Cardiol; 2001 Aug; 88(3):265-9. PubMed ID: 11472705
[TBL] [Abstract][Full Text] [Related]
37. Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus.
Ciriacks K; Coly G; Krishnaswami S; Patel SB; Kidambi S
Metab Syndr Relat Disord; 2015 Mar; 13(2):84-90. PubMed ID: 25490061
[TBL] [Abstract][Full Text] [Related]
38. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
39. Gas chromatography analysis of serum cholesterol synthesis and absorption markers used to predict the efficacy of simvastatin in patients with coronary heart disease.
Wu WF; Wang QH; Zhang T; Mi SH; Liu Y; Wang LY
Clin Biochem; 2013 Aug; 46(12):993-998. PubMed ID: 23598259
[TBL] [Abstract][Full Text] [Related]
40. Clinical study on the effect of simvastatin on butyrylcholinesterase activity.
Muacević-Kataneca D; Bradamante V; Reinec Z; Sucić M; Poljicanin T; Busljeta I; Metelko Z
Arzneimittelforschung; 2005; 55(5):271-5. PubMed ID: 15960426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
